A phase 1b clinical trial by a valuable team of researchers explores the safety, immunogenicity, and optimal dosing of MVA-MERS-S, a modified vaccinia Ankara-based candidate vaccine for MERS-CoV.The study found that a 56-day interval between doses at 108 PFU generated the strongest immune response compared to other schedules. The vaccine was well-tolerated, with no serious adverse events reported. MVA-MERS-S showed strong immunogenicity, particularly in individuals previously exposed to SARS-CoV-2. These findings provide a foundation for future vaccine strategies in high-risk populations.
